Last reviewed · How we verify

NCT05170217: eCBD

Reducing the Harmful Effects of Cannabis Use: Finding the Optimal CBD:THC Ratio

Completed NA Last updated 27 December 2021
What this trial tests

NA trial testing THC in Cannabis Use in 46 participants. Completed in 9 June 2019.

Timeline
8 November 2017
Primary endpoint
9 June 2019
9 June 2019

Quick facts

Lead sponsorKing's College London
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposebasic science
Enrollment46
Start date8 November 2017
Primary completion9 June 2019
Estimated completion9 June 2019
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

King's College London

Who can join

Adults 21 to 50, any sex, with Cannabis Use. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will recruit healthy volunteers who use cannabis infrequently. Each participant will attend the laboratory on five occasions: an initial visit to check that they are safe to join the study and four days of testing. Participants will be administered, in a randomized order, vaporized cannabis containing one of four different ratios of CBD:THC (0:1, 1:1, 2:1, 3:1). The cannabis administration will follow a standardised inhalation procedure using a medical-grade vaporizer device. Participants will complete a series of tasks measuring cognition, psychosis, anxiety and other subjective experiences. The study will be carried out at the NIHR-Wellcome Trust Clinical Research Facility at King's College Hospital.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.
    Englund A, Oliver D, Chesney E, Chester L, et al · · 2023 · cited 64× · PMID 36380220 · DOI 10.1038/s41386-022-01478-z
  2. Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study.
    Chester LA, Englund A, Chesney E, Oliver D, et al · · 2024 · cited 14× · PMID 36493386 · DOI 10.1089/can.2022.0174
  3. Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over study.
    Oliver D, Englund A, Chesney E, Chester L, et al · · 2024 · cited 3× · PMID 37821096 · DOI 10.1111/add.16353

Verify or expand the search:

Other trials of THC

Trials testing the same drug.

Other recruiting trials for Cannabis Use

Currently open trials in the same condition.

Other King's College London trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05170217.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing